Pelvic Floor Muscles Training After Radical Prostatectomy.

Urinary Incontinence Clinical Trial

Official title:

Evaluation of the Effectiveness of Pelvic Floor Muscles Training for Urinary Incontinence After Radical Prostatectomy. Pilot Study.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04172519
• Other study ID #: NicolausCU
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 1, 2018
• Est. completion date: September 2021

Study information

• Verified date: April 2020
• Source: Nicolaus Copernicus University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prostate cancer (PCa) is a malignant tumor commonly diagnosed among men in the USA and Europe. About 81% of cases of prostate cancer are detected early on, which allows patients to receive effective treatment. High risk cancer patients may undergo radical prostatectomy (RP) which includes the removal of the entire prostate gland together with both seminal vesicles, prostatic urethra, and bilateral pelvic lymph nodes. Even though RP has been improved over decades, patients are still at risk of surgical and post-surgical complications. The most common complications include urinary incontinence and erectile dysfunction. Pelvic floor muscle training is recognized as the physiotherapeutic modality for the treatment of urinary incontinence in men after radical prostatectomy. This method is recommended by the European Association of Urology. However, the literature analysis and systematic review carried out by our team prove that there are relatively few clinical trials with a well-developed research protocol assessing this form of therapy. In order to objectify the effects of therapy, we will assess both psychosocial aspects, as well as try to answer the question whether biochemical parameters can be a marker of pelvic floor muscles. In previous own research, we obtained promising results by examining biochemical parameters during pelvic floor muscle activity in women with stress urinary incontinence.

Description:

The subject of the study is to assess the impact of physiotherapeutic intervention in the form of pelvic floor muscle training in patients after laparoscopic radical prostatectomy. A randomized control trials will be carried out on a group of about 300 people (men over 40 years of age) before and after radical prostatectomy. The examined people will be divided into 4 groups and will be assessed before and after surgery: 2 weeks, 6 weeks, 3 months and 6 months. All participants in the study will undergo tests such as: urodynamic, biochemical, MRI, standardized questionnaires regarding the quality of life, physiotherapeutic assessment, histopathological assessment, and cancer progression assessment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 76
• Est. completion date: September 2021
• Est. primary completion date: October 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

• patients diagnosed with prostate cancer qualified for surgery

• patients who underwent radical prostatectomy

• 40-85 years of age.

• patients who gave their written consent to participate in the study

• patient's joining the program will always be preceded by a medical consultation and exclusion of contraindications to therapy

• patients able to understand Polish.

Exclusion Criteria:

• classical retropubic operation,

• classical perineal surgery,

• operation assisted by daVinci robot,

• partial prostate surgery,

• transurethral resection of the prostate (TURP),

• the research will not involve incapacitated persons, soldiers of the basic service, persons deprived of their liberty and remaining in official or other dependence with the persons conducting the examination,

• patient's disagreement to participate in pelvic floor muscle training

• intraoperative and postoperative complications preventing the introduction of early rehabilitation ((damage to the external sphincter, urinary tract infection, bladder neck narrowing),

• prostate cancer recurrence,

• no incontinence after surgery,

• urinary incontinence before surgery,

• previous prostate surgery.

Related Conditions & MeSH terms

• Enuresis
• Pelvic Floor Disorders
• Prostatectomy
• Urinary Incontinence

Intervention

Other:
• Pre- and post prostatectomy supervised PMFT
intervention before and after surgery, supervised exercises
• Unsupervised PMFT
intervention after surgery, unsupervised exercises
• Supervised PMFT
intervention after surgery and supervised exercise

Locations

Country	Name	City	State
Poland	Nicolaus Copernicus University in Torun Collegium Medicum in Bydgoszcz, Department of Physiotherapy	Bydgoszcz
Poland	The Jan Biziel Hospital, Department of Urology	Bydgoszcz

Sponsors (1)

Lead Sponsor	Collaborator
Nicolaus Copernicus University

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	General Self Efficacy Scale (GSES)	The raw scores are afterward transformed into standardized sten scores. The higher the score, the higher are self-efficacy beliefs. Score ranges are defined as follows: 1-4 sten, low scores; 5-6 sten, average scores; and 7-10 sten, high scores.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Self Esteem Scale (SES)	General Self-Assessment Level Scale is a tool that allows you to assess the level of general self-assessment. It consists of 10 diagnostic statements. The test is designed to indicate the four-level scale, to what extent patients agree with each of these statements. The raw results obtained are converted into standardized sten standards. The following scoring is taken: 1-4 sten - low results; 5-6 sten - average results; 7-10 sten - high results.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Beck Depression Inventory - II (BDI - II)	The BDI questionnaire has been the most widely used self-report depression scale. The tool is used in research on mental disorders and to assess the mood of patients suffering from various medical conditions, including oncological, urological, gynecological, and neurological diseases. The BDI-II questionnaire is a 21-item scale with individual item scores ranging from 0 (no symptoms) to 3 (severe symptoms). A total score of 0-8 is considered as no depression, 9-18 indicates moderate depression, and a score of 18+ is considered as severe depression.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Acceptance of Disease Scale (AIS)	Acceptance of Disease Scale (AIS) which determines the extent to which the patient accepts his own illness and assesses the severity of negative emotions associated with it. This tool contains 8 statements describing the consequences of the disease. Each statement is scored 1-5 (1- lack of acceptance of the disease; 2-5 good adaptation to the disease situation).	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	International Index of Erectile Function - 5 (IIEF - 5)	The International Index of Erectile Function - 5, which consists of 15 items and 5 domains, is a psychometrically valid and reliable instrument that was developed through consultations with an international panel of experts for use in determining efficacy of treatment in controlled clinical trials.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Expanded Prostate Cancer Index Composite-26 (EPIC-26)	EPIC-26, contains five symptom domains (urinary incontinence, urinary irritative/obstructive, sexual, bowel, hormonal), scored from 0 (worst) to 100 (best), that can be tracked over time to understand symptom burden, functional outcomes and the impact of side effect management strategies.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	EORTC Quality of life Questionnaire -Prostate Cancer Module (EORTC QLQ-PR25)	The prostate-specific module EORTC QLQ-PR25 is a self-administered questionnaire that includes 4 subscales for assessment of Urinary symptoms (9 items, labeled US31-US39), Bowel symptoms (4 items, BS40-BS43), Hormonal treatment-related symptoms (6 items, TS44-TS49), and Sexual activity and function (6 items, SX50-SX55).	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	EORTC Quality of Life Questionnaire core 30 (EORTC QLQ-C30)	EORTC QLQ-C30 assesses HRQoL in cancer patients with 15 scales, each ranging in scores from 0 to 100.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	International Prostate Symptom Score (I-PSS)	Each question concerning urinary symptoms allows the patient to choose one out of six answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic).	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Sex Hormone Binding Globulin (SHGB)	Six milliliters of blood will be collected from each subject after at least 12 hours fasting. Participants had to fast over night with the last meal before 7 pm on the day before the investigation.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Luteinizing Hormone (LH)	Six milliliters of blood will be collected from each subject after at least 12 hours fasting. Participants had to fast over night with the last meal before 7 pm on the day before the investigation.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Follicle Stimulating Hormone (FSH)	Six milliliters of blood will be collected from each subject after at least 12 hours fasting. Participants had to fast over night with the last meal before 7 pm on the day before the investigation.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Free testosterone	The test is performed in cases where the interpretation of total testosterone results is questionable or impossible due to fluctuations in SHBG levels.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Total testosterone	Six milliliters of blood will be collected from each subject after at least 12 hours fasting. Participants had to fast over night with the last meal before 7 pm on the day before the investigation.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Colecalciferol (vitamin D3.)	In the blood should be in the range of 30-50 nmol / l (20 ng / ml).	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Myostatin	Six milliliters of blood will be collected from each subject after at least 12 hours fasting into Vacuette tubes with EDTA anticoagulant. Participants had to fast over night with the last meal before 7 pm on the day before the investigation.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Irisin	Six milliliters of blood will be collected from each subject after at least 12 hours fasting into Vacuette tubes with EDTA anticoagulant. Participants had to fast over night with the last meal before 7 pm on the day before the investigation.	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	N-terminal telopeptide of type 1 collagen (NTX)	Morning urine collection	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	C-telopeptide of type 1 collagen (CTX)	Morning urine collection	1 day 2 weeks before surgery and assessment of change from baseline at 6 weeks, 3 months and 6 months after operation
Primary	Multi-parametric pelvic magnetic resonance (mp NMR)	with evaluation of the prostate gland before surgery and lodge of prostate gland after radical prostatectomy	2 days
Primary	Gleason Score	The Gleason Score ranges from 1-5 and describes how much the cancer from a biopsy looks like healthy tissue (lower score) or abnormal tissue (higher score). Most cancers score a grade of 3 or higher.	1 day
Primary	Histopathological examination questionnaire	operator's assessment	1 day
Primary	TNM Classification of Malignant Tumors (TNM)	Small, low-grade cancer, no metastasis, no spread to regional lymph nodes, cancer completely removed, resection material seen by pathologist: pT1 pN0 M0 R0 G1; this grouping of T, N, and M would be considered Stage I.; Large, high grade cancer, with spread to regional lymph nodes and other organs, not completely removed, seen by pathologist: pT4 pN2 M1 R1 G3; this grouping of T, N, and M would be considered Stage IV.	1 day